/EINPresswire.com/ -- Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Palace Hotel in New York City.

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, 455 Madison Avenue at 50th Street, NYC.
Date: September 12, 2016
Time: 4:40PM Eastern
Location: Kennedy II, 4th Floor

Robert Brooke, CEO of Vitality Biopharma, will deliver the Company's corporate presentation and discuss recent business highlights. In addition to the presentation, Mr. Brooke will also be available for one-on-one meetings.

To find out more about Vitality Biopharma and the important work it performs, please visit www.vitality.bio.

About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, will be held on from September 8 to September 10, 2015, at the St. Regis Hotel in New York. More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees. The event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities.

About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact
Vitality Biopharma
Investor Relations
info@vitality.bio
1-530-231-7800
www.vitality.bio